Inclusion Criteria:

- Pathological diagnosis of either squamous cell carcinoma or adenocarcinoma of the
esophagus or gastroesophageal junction.

- Clinical stage IIA, IIB or III without metastatic disease

- Patients must have documented EGFR status or have tumor tissue available for
assessment of EGFR status by IHC

- Patients must be surgical candidates as determined by surgical consult.

- Patients must agree to surgery.

- ECOG performance status 0 or 2

- Absolute neutrophil count (ANC) > 1,000 mm3

- Platelet count > 75,000 mm3· Hemoglobin > 10g/dL

- Bilirubin < 2.5 X upper limit of normal

- AST (SGOT) or ALT (SGPT) < 5.0 ´ upper limit of normal

- Creatinine < 2.0 X upper limit of normal

Exclusion Criteria:

- No history of or current brain metastasis.

- No significant history of uncontrolled cardiac disease; i.e. uncontrolled
hypertension, unstable angina, recent myocardial infarction (within prior 6 months),
uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection
fraction.

- No history of interstitial pneumonitis or pulmonary fibrosis, or suspicion of
interstitial pneumonitis or pulmonary fibrosis on imaging.

- No concurrent chemotherapy not indicated in the study protocol or any other
investigational agent(s).

- No prior use of radiation or chemotherapy for cancer of the esophagus or GE junction

- No prior therapy that specifically and directly targets the EGFR pathway (such as
kinase inhibitors and antibodies directed against the HER family receptors).

- No prior severe infusion reaction to a monoclonal antibody.

- No major surgery within 28 days prior to being registered for protocol therapy.

- No clinically significant infections as judged by the treating investigator.

- No acute hepatitis or known HIV.

- No other active malignancies.

- Negative pregnancy test.

- No female patients currently breastfeeding.